PL362838A1 - Antagoniści somatostatyny - Google Patents

Antagoniści somatostatyny

Info

Publication number
PL362838A1
PL362838A1 PL02362838A PL36283802A PL362838A1 PL 362838 A1 PL362838 A1 PL 362838A1 PL 02362838 A PL02362838 A PL 02362838A PL 36283802 A PL36283802 A PL 36283802A PL 362838 A1 PL362838 A1 PL 362838A1
Authority
PL
Poland
Prior art keywords
somatostatin antagonists
somatostatin
antagonists
Prior art date
Application number
PL02362838A
Other languages
English (en)
Inventor
David H. Coy
William A. Murphy
Walajapet G. Rajeswaran
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of PL362838A1 publication Critical patent/PL362838A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02362838A 2001-03-08 2002-03-05 Antagoniści somatostatyny PL362838A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27430801P 2001-03-08 2001-03-08
PCT/US2002/006676 WO2002072602A2 (en) 2001-03-08 2002-03-05 Somatostatin antagonists

Publications (1)

Publication Number Publication Date
PL362838A1 true PL362838A1 (pl) 2004-11-02

Family

ID=23047655

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02362838A PL362838A1 (pl) 2001-03-08 2002-03-05 Antagoniści somatostatyny

Country Status (16)

Country Link
US (3) US7378488B2 (pl)
EP (1) EP1372688B1 (pl)
JP (3) JP4204322B2 (pl)
AR (1) AR035942A1 (pl)
AT (1) ATE394114T1 (pl)
AU (1) AU2002258465B2 (pl)
CA (1) CA2439498A1 (pl)
CZ (1) CZ299362B6 (pl)
DE (1) DE60226419D1 (pl)
DK (1) DK1372688T3 (pl)
ES (1) ES2306766T3 (pl)
HU (1) HUP0401535A3 (pl)
NO (1) NO20033911L (pl)
PL (1) PL362838A1 (pl)
RU (2) RU2263678C2 (pl)
WO (1) WO2002072602A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3290302A (en) * 2000-10-20 2002-04-29 Univ Tulane Urotensin-ii agonists and antagonists
RU2263678C2 (ru) 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
JP2004531520A (ja) * 2001-04-09 2004-10-14 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ソマトスタチンアゴニスト
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US8017575B2 (en) * 2004-12-15 2011-09-13 Wilfred Wayne Lautt Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
PL2383289T3 (pl) * 2006-10-16 2015-03-31 Salk Inst Biological Studies Antagoniści somatostatyny selektywni względem receptora (SSTR2)
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
SG10201400650QA (en) 2008-10-29 2014-05-29 Kaneka Corp Method For Producing L-Amino Acid
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
US11279732B2 (en) 2016-02-09 2022-03-22 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
WO2021111503A1 (ja) * 2019-12-02 2021-06-10 花王株式会社 光吸収層及びその製造方法、分散液、光電変換素子、並びに太陽電池

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034567B1 (en) * 1980-02-14 1984-11-07 Sandoz Ag A method for the total synthesis of cyclosporins and novel cyclosporins
JPS63146850A (ja) 1986-11-12 1988-06-18 メルク エンド カムパニー インコーポレーテツド フエニルアラニル−ヒスチジン代用成分を有するレニン阻害剤
EP0278158A3 (en) 1986-11-12 1990-05-23 Merck & Co. Inc. Renin inhibitors containing phenylalanyl-histidine replacements
EP0273696A2 (en) 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
CH679045A5 (pl) 1987-06-29 1991-12-13 Sandoz Ag
JPS6426599U (pl) 1987-08-10 1989-02-15
DE68928278T2 (de) 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
ES2091907T3 (es) * 1989-12-08 1996-11-16 Univ Tulane Analogos octapeptidos de somatostina con una threonina en la sexta posicion.
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
JPH06509075A (ja) 1991-07-01 1994-10-13 ユニヴァーシティ テクノロジーズ インターナショナル インコーポレイテッド GnRH及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
HU224350B1 (hu) 1993-08-09 2005-08-29 Société de Conseils de Recherches et d'ApplicationScientifiques, S.A.S. Á Gyógyhatású peptidszármazékok
HU221092B1 (en) * 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
GB9402767D0 (en) 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
IL130166A0 (en) * 1996-12-04 2000-06-01 Sod Conseils Rech Applic Somatostatin antagonists
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60232203D1 (de) * 2001-03-06 2009-06-10 Il Consorzio Ferrara Richerche Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen
RU2263678C2 (ru) 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
JP2004531520A (ja) 2001-04-09 2004-10-14 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ソマトスタチンアゴニスト

Also Published As

Publication number Publication date
CZ299362B6 (cs) 2008-07-02
JP2006342171A (ja) 2006-12-21
JP2004532824A (ja) 2004-10-28
WO2002072602A2 (en) 2002-09-19
HUP0401535A3 (en) 2009-07-28
JP4204322B2 (ja) 2009-01-07
HUP0401535A2 (hu) 2004-12-28
DK1372688T3 (da) 2008-08-25
US20040181032A1 (en) 2004-09-16
RU2005117614A (ru) 2006-11-20
JP2008255120A (ja) 2008-10-23
WO2002072602A3 (en) 2003-03-20
NO20033911D0 (no) 2003-09-04
RU2328504C2 (ru) 2008-07-10
EP1372688A4 (en) 2006-06-14
ES2306766T3 (es) 2008-11-16
AR035942A1 (es) 2004-07-28
CA2439498A1 (en) 2002-09-19
RU2003129807A (ru) 2005-03-20
RU2263678C2 (ru) 2005-11-10
US7408024B2 (en) 2008-08-05
AU2002258465B2 (en) 2006-01-19
US20080020970A1 (en) 2008-01-24
US7378488B2 (en) 2008-05-27
NO20033911L (no) 2003-10-29
EP1372688A2 (en) 2004-01-02
EP1372688B1 (en) 2008-05-07
DE60226419D1 (de) 2008-06-19
ATE394114T1 (de) 2008-05-15
CZ20032281A3 (cs) 2004-01-14
US20080171853A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
IL165841A0 (en) Mchir antagonists
CA97154S (en) Drill
AU2002341834A1 (en) Antagonists
SI1671949T1 (sl) Substituirani pridinilamini
HU0101106D0 (en) Id alsorithm
CA97153S (en) Drill
IL158051A0 (en) Somatostatin agonists
PL362643A1 (pl) Podstawione fluoroalkoksyfenylosulfonylomoczniki
DK1372688T3 (da) Somatostatin-antagonister
PL368050A1 (pl) Podstawione 4-aminocykloheksanole
GB0104554D0 (en) New uses
IL153176A0 (en) New phenylpiperazines
GB0112342D0 (en) Polypeptides
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
PL364601A1 (pl) Podstawione związki benzoheterocykliczne zawierające azot
PL364090A1 (pl) Nowe benzyloaminopirymidyny
GB0125051D0 (en) GT speedlock
GB0124684D0 (en) Tile
CA93112S (en) Drill
CA94144S (en) Drill
GB0006860D0 (en) Antagonists
GB0009125D0 (en) Antagonists
GB0120289D0 (en) V place
GB0127164D0 (en) Micro-pin interface
GB0118302D0 (en) Tiles

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)